Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
October is Liver Cancer Awareness Month.
Combining Imfinzi and Avastin with TACE led to better treatment outcomes.
What’s more, Black patients have poorer survival outcomes compared to people of other racial groups.
Nearly half of all deaths within five years of an ALD diagnosis were due to liver-related causes.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
Experts predict that more than a million people could die from liver cancer worldwide in 2040.
A study has identified a number of potential biomarkers that clinicians can use to predict how their patients will respond to treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.